摩根大通证券公司：重申Abivax评级

证券之星

2025/01/10

摩根大通证券公司：重申abivax(ABVX.US)评级，由优于大市调整至优于大市评级,目标价由33.00美元调整至33.00美元。Abivax S.A.(ABVX.US)公司简介：Abivax SA是一家总部位于法国的临床阶段生物技术公司，专注于开发利用人体自然调节机制稳定慢性炎症性疾病患者免疫反应的疗法。他们正在3期临床试验中评估其候选药物obefazimod，此药物用于治疗患有中度至重度...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2502896251"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502896251\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2502896251?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-01-10 23:27","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2502896251","market":"us","top_or_hot":-1,"title":"摩根大通证券公司：重申Abivax评级","media":"证券之星","content":"<div>\n<p>摩根大通证券公司：重申abivax(ABVX.US)评级，由优于大市调整至优于大市评级,目标价由33.00美元调整至33.00美元。Abivax S.A.(ABVX.US)公司简介：Abivax SA是一家总部位于法国的临床阶段生物技术公司，专注于开发利用人体自然调节机制稳定慢性炎症性疾病患者免疫反应的疗法。他们正在3期临床试验中评估其候选药物obefazimod，此药物用于治疗患有中度至重度...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110233450a21d1d7c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>摩根大通证券公司：重申Abivax评级</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n摩根大通证券公司：重申Abivax评级\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-10 23:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110233450a21d1d7c&s=b><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>摩根大通证券公司：重申abivax(ABVX.US)评级，由优于大市调整至优于大市评级,目标价由33.00美元调整至33.00美元。Abivax S.A.(ABVX.US)公司简介：Abivax SA是一家总部位于法国的临床阶段生物技术公司，专注于开发利用人体自然调节机制稳定慢性炎症性疾病患者免疫反应的疗法。他们正在3期临床试验中评估其候选药物obefazimod，此药物用于治疗患有中度至重度...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110233450a21d1d7c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110233450a21d1d7c&s=b","article_id":"2502896251","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110233450a21d1d7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2502896251","pubTimestamp":1736522856,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"摩根大通证券公司：重申abivax(ABVX.US)评级，由优于大市调整至优于大市评级,目标价由33.00美元调整至33.00美元。Abivax S.A.(ABVX.US)公司简介：Abivax SA是一家总部位于法国的临床阶段生物技术公司，专注于开发利用人体自然调节机制稳定慢性炎症性疾病患者免疫反应的疗法。他们正在3期临床试验中评估其候选药物obefazimod，此药物用于治疗患有中度至重度活动性溃疡性结肠炎的成人。其最初重点是炎症性肠病，即涉及胃肠道炎症的慢性疾病，其中两种最常见的形式是UC和CD。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"JPMorgan Securities: Reaffirming Abivax Rating","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":0.9},"content_text":"摩根大通证券公司：重申abivax(ABVX.US)评级，由优于大市调整至优于大市评级,目标价由33.00美元调整至33.00美元。Abivax S.A.(ABVX.US)公司简介：Abivax SA是一家总部位于法国的临床阶段生物技术公司，专注于开发利用人体自然调节机制稳定慢性炎症性疾病患者免疫反应的疗法。他们正在3期临床试验中评估其候选药物obefazimod，此药物用于治疗患有中度至重度活动性溃疡性结肠炎的成人。其最初重点是炎症性肠病，即涉及胃肠道炎症的慢性疾病，其中两种最常见的形式是UC和CD。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}